Quarterly report pursuant to Section 13 or 15(d)

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.24.2.u1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 02, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
May 01, 2024
Jan. 17, 2019
Allowance for doubtful accounts   $ 0   $ 0   $ 0    
Advertising costs   11,590 $ 33,638 24,208 $ 62,786      
Impairment of intellectual property $ 47,980 0 0 $ 0 47,980      
Aging categories to estimate risk, description       The Company used the following aging categories to estimate the risk of delinquency status: (i) 0 days past due; (ii) 1-30 days past due; (iii) 31-60 days past due; (iv) 61-90 days past due; and (v) over 90 days past due        
Impairment loss         47,980      
Grant funding during the first year             $ 4,131,123 $ 2,842,430
Grant funding             11,029,977  
Grant funding during the second year             3,638,268 2,831,838
Grant funding during the third year             $ 3,260,586 3,453,367
Grant additional funding during the third year               $ 99,431
Grant receivables   109,736   $ 109,736   76,266    
Deferred income       0   0    
Grant income   518,667 248,006 631,630 489,155      
F & A indirect costs   0   0   $ 0    
Grant funding indirect cost       516,218        
Research and development expenses   $ 536,362 $ 238,419 $ 750,196 $ 475,806      
Ownership percentage       50.00%        
Royalty obligations description       The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued        
Description of Non-Controlling Interest       Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest        
Royalty obligations, net       $ 7,171,200        
Minimum [Member]                
Property plant and equipment estimated useful lives       5 years        
Maximum [Member]                
Property plant and equipment estimated useful lives       15 years